A Phase 4 interventional study of Silodosin Capsules and Tamsulosin in Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms, sponsored by Xintian Pharmaceutical. Completed at 8 sites in China. Open to male participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Xintian Pharmaceutical · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Lower Urinary Tract Symptoms with a site in China — 10 open to participants now, 10 under way, 1 of them phase 3. Lower Urinary Tract Symptoms · China.
Among the 21 studies in Lower Urinary Tract Symptoms with a site in China, this one is the 8th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 in phase 4, and was the 8th registered.
417 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.
Browse Lower Urinary Tract Symptoms studies →10 of the 21 studies in Lower Urinary Tract Symptoms with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 50+ · Men only
Chinese PLA General Hospital · Sites in China
Ages 40+ · Men only · Healthy volunteers
Société Internationale d'Urologie · Sites in China, United States, Canada and 18 more countries
Ages 18+ · Men only
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Sites in China
Ages 40–80 · Men only
Zhongda Hospital · Sites in China
Ages 50–85 · Men only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 59 Lower Urinary Tract Symptoms studies recruiting now, 39 (66%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 60 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is close to the median of 100 across 272 interventional studies indexed under Lower Urinary Tract Symptoms.
Median enrollment 110 across the 16 interventional studies, 7,500 across the 5 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 21 have an industry lead sponsor. The 10 most frequent:
Xintian Pharmaceutical is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Xintian Pharmaceutical has 1 study filed under Lower Urinary Tract Symptoms — fewer than ten, so there is no comparison to draw.
4 of the studies in Lower Urinary Tract Symptoms with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07146386Phase 3Shanghai Huilun Pharmaceutical Co., Ltd.A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia | 2027-01 |
| NCT07710794Qilu Hospital of Shandong UniversityTranscutaneous Tibial Nerve Stimulation (TTNS) Patch in the Treatment of Patients With Lower Urinary Tract Symptoms (LUTS) After Benign Prostatic Hyperplasia (BPH) Surgery | 2027-01-31 |
| NCT06867315First Affiliated Hospital of Zhejiang UniversityTransperineal Irreversible Electroporation for Benign Prostatic Hyperplasia | 2027-05-29 |
| NCT07736807Zhongda HospitalEarly Electroacupuncture for Post-TURP LUTS | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Lower Urinary Tract Symptoms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objective: To evaluate the efficacy and safety of Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules.
Study design: A multicenter, prospective, randomized, investigator-blind, active controlled clinical study.
Interventions:
Group A: Oral Tamsulosin Hydrochloride Capsules for 12 weeks. Group B: Oral l Silodosin Capsules for 12 weeks.
Sample size: 108
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients take tamsulosin hydrochloride capsules (1 tablet each time, once daily)
Drug: Tamsulosin
Patients take Silodosin Capsules ( Qianweitai®, 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner)
Drug: Silodosin Capsules
Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule,1 capsule/time, bid, after breakfast and dinner.
Also known as: Qianweitai
Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
International Prostate Symptom Score(IPSS)
Changes of IPSS scores at the 12th week of treatment compared with baseline scores. The scores of the scale ranged from 0 to 35. The higher the score, the more severe the symptoms are.
Time frame: 12 week
International Prostate Symptom Score(IPSS) total score
Changes of IPSS scores at 1, 2, 4 and 8 weeks after treatment compared with baseline scores. The scores of the scale ranged from 0 to 35. The higher the score, the more severe the symptoms are.
Time frame: 1, 2, 4 and 8 weeks
IPSS Stimulus score
IPSS Stimulation Score at 12 weeks (Sum of Question 2, 4, 7) compared with baseline. The scores of the scale ranged from 0 to 15. The higher the score, the more severe the symptoms are.
Time frame: 12 weeks
IPSS obstruction score
Changes of IPSS obstruction score (sum of question 1, 3, 5, 6) at 12 weeks after treatment compared with baseline. The scores of the scale ranged from 0 to 20. The higher the score, the more severe the symptoms are.
Time frame: 12 weeks
IPSS total score severity
Distribution of IPSS total score severity grades at 12 weeks. The scores of the scale were divided into three grades: mild (0-7), moderate (8-19) and severe (20-35).
Time frame: 12 week
Quality of life (QoL) score
Changes in scores at 4, 8 and 12 weeks of treatment compared with baseline.The scores of the scale ranged from 0 to 6. The higher the score, the more severe the symptoms are.
Time frame: 4, 8 and 12 weeks
Maximum urinary flow rate (Qmax)
The change of Qmax at 12 weeks of treatment compared with baseline.
Time frame: 12 weeks
Residual urine volume (PVR)
Changes of PVR at 12 weeks of treatment compared with baseline.
Time frame: 12 weeks
Patient response rate
Patient response rate is defined as the proportion of patients whose IPSS total score decreased by ≥ 25% compared with baseline value after treatment.
Time frame: 12 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Sep 2024, 23 months.
Of 18 phase 4 interventional studies under Lower Urinary Tract Symptoms, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 29. This study's 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Silodosin
Lower Urinary Tract Symptoms →
Xintian Pharmaceutical